Last reviewed · How we verify

Clarity Pharmaceuticals Ltd — Portfolio Competitive Intelligence Brief

Clarity Pharmaceuticals Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
64Cu-SAR-bisPSMA 64Cu-SAR-bisPSMA phase 3 Radiopharmaceutical; PET imaging agent PSMA (prostate-specific membrane antigen) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GE Healthcare · 1 shared drug class
  2. Queen's Medical Center · 1 shared drug class
  3. Radiomedix, Inc. · 1 shared drug class
  4. Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class
  5. UMC Utrecht · 1 shared drug class
  6. University of Colorado, Denver · 1 shared drug class
  7. University of Saskatchewan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Clarity Pharmaceuticals Ltd:

Cite this brief

Drug Landscape (2026). Clarity Pharmaceuticals Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clarity-pharmaceuticals-ltd. Accessed 2026-05-16.

Related